
Europe GCSF-Filgastrim Market By Route of Administration (Intravenous, Subcutaneous), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders and Others), By Country – Global Forecast to 2030
-
20010
-
June 2021
-
150
-
PDF
-
-
Marketresearch.Biz announces publication of its most recently generated research report titled, “Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market by Route of Administration (Intravenous & Subcutaneous), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders & Other Applications), and by Country – Global Forecast to 2030”, which offers a holistic view of the Europe granulocyte colony stimulator factor (GCSF-filgastrim) market through systematic segmentation that covers every aspect of the target market. The Europe granulocyte colony stimulator factor (GCSF-filgastrim) market is projected to be US$ 2,251.8 Mn in 2020 to reach US$ 4,371.4 Mn by 2030 at a CAGR of 7.0%.
Granulocyte colony-stimulating factor (GCSF) is a glycoprotein that simulates the bone marrow to produce granulocyte (a type of white blood cell) and stem cells and release them into the bloodstream. A number of various tissues produce a type of colony stimulator factor, known as cytokine and hormone however, pharmaceutical analogs of this naturally occurring GCSF are filgrastim and lenograstim. Filgrastim is used for treatment of low neutrophil count, which me occur owing to various life risking diseases such as HIV/AIDs, following chemotherapy, or radiation poisoning among others.
Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Revenue (US$ Mn), 2020–2030.
The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is an important factor that is expected to fuel the revenue growth for the granulocyte-colony stimulating factor market in Europe. Also, the rising prevalence of cancer patients owing to unhealthily lifestyles, consumption of processed food, alcohol, and severe smoking habits is a factor that is expected to further bolster the projected financial growth of this given market over the coming years.Although the high costs associated with initial treatment of chemotherapy, coupled with the high cost of prophylaxis with G-CSF and stringent regulations of respective national authorities towards approval of biosimilar drugs, and high cost of development of this drug are also certain factors that are expected to hamper the revenue growth of this given market.
Approval of biosimilar drugs such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper as compared to currently available drugs. These biosimilar drugs are expected to create financial growth opportunities for this given market over the forecast period. Moreover, rapid R&D has been witnessed in recent years for the development of new and effective drugs for GCSF that cost-effective as well, resulting in the increased success rate of clinical trials. This trend is expected to continue and further amplify the projected profit margins for this target market in Europe in the coming years.
Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Attractiveness Analysis by Route of Administration, 2014–2030.
The granulocyte colony stimulator factor (GCSF Filgastrim) market in Europe is segmented country-wise into Germany, UK, France, Russia, Italy, Spain, and Rest of Europe, respectively. Among these aforementioned Country, the markets in the Germany segment are expected to register the majority revenue shares of the granulocyte colony stimulator factor (GCSF filgastrim) market in Europe.
The research report on the Europe granulocyte colony stimulator factor (GCSF-Filgastrim) market includes profiles of some of the major companies such as Novartis AG (Sandoz), Pfizer Inc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, Biocon Ltd, Dong-A Socio Holdings Co., Ltd, BioCad.
Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market Segmentation Based on Route of Administration, Application, and Region
Based on Route of Administration:
- Intravenous
- Subcutaneous
Based on Application:
- Oncological Diseases
- Blood Disorders
- Growth Hormone Deficiencies
- Chronic and Autoimmune Disorders
- Other Applications
Based on Country:
- Germany
- UK
- France
- Russia
- Italy
- Spain
- Rest of Europe
-
- Novartis AG (Sandoz)
- Pfizer Inc
- Amgen Inc
- Teva Pharmaceutical Industries Ltd
- Stada Arzneimittel AG
- Dr. Reddy's Laboratories Ltd
- Intas Pharmaceuticals Ltd
- Biocon Ltd
- Dong-A Socio Holdings Co. Ltd
- BioCad.
-
- Chapter 1 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Overview
- 1.1 Introduction
- 1.2 Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market Segmentation Based on Route of Administration, Application, and Region
- 1.3 Drivers for the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
- 1.4 Restraints for the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
- 1.5 Opportunities for the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
- 1.6 Trends in the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
- 1.7 Drivers & Restraints Impact Analysis
- 1.8 PESTE Analysis
- 1.9 PORTER'S Five Forces Analysis
- 1.10 Macro-Economic Factors
- 1.11 The COVID-19 Heat Map: Impact on Industry Sectors
- 1.12 Market Investment Feasibility Analysis
- 1.13 COVID-19 Impact
- 1.14 Clinical Trial Analysis of Granulocyte Colony Stimulator Factor
- 1.15 Opportunity Map Analysis
- 1.15.1 Optimistic Scenario
- 1.15.2 Likely Scenario
- 1.15.3 Conservative Scenario
- 1.16 Opportunity Orbits
- 1.17 Regional Market Share and BPS Analysis of Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market
- Chapter 2 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Overview
- 2.1 Europe Granulocyte Colony Stimulating Factor Market by Route of Administration
- 2.1.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Route of Administration (2014-2030)
- 2.1.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Market Share by Route of Administration in 2020
- 2.1.3 Europe Granulocyte Colony Stimulating Factor Market Attractiveness Analysis by Route of Administration, 2014–2030
- 2.2 Europe Granulocyte Colony Stimulating Factor Market by Application
- 2.2.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Application (2014-2030)
- 2.2.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Market Share by Application in 2020
- 2.2.3 Europe Granulocyte Colony Stimulating Factor Market Attractiveness Analysis by Application, 2014–2030
- 2.3 Europe Granulocyte Colony Stimulating Factor Market Outlook by Country
- 2.3.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Country (2014-2030)
- 2.3.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Market Share by Country in 2020
- 2.3.3 Europe Granulocyte Colony Stimulating Factor Market Attractiveness Analysis by Country, 2014–2030
- 2.4 Europe Granulocyte Colony Stimulating Factor Market Outlook (2014–2030)
- 2.4.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) (2014–2021)
- 2.4.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) (2022–2030)
- 2.5 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) by Country
- 2.5.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Country (2014–2021)
- 2.5.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Country (2022–2030)
- 2.6 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) by Route of Administration
- 2.6.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Route of Administration (2014–2021)
- 2.6.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Route of Administration (2022–2030)
- 2.7 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) by Application
- 2.7.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Application (2014–2021)
- 2.7.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Application (2022–2030)
- 2.8 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate Comparison 2015–2030
- 2.8.1 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate by Country
- 2.8.2 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate by Route of Administration
- 2.8.3 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate by Application
- 2.9 Europe Granulocyte Colony Stimulating Factor Market Share Comparison 2014–2030
- 2.9.1 Europe Granulocyte Colony Stimulating Factor Market Share by Country
- 2.9.2 Europe Granulocyte Colony Stimulating Factor Market Share by Route of Administration
- 2.9.3 Europe Granulocyte Colony Stimulating Factor Market Share by Application
- 2.1 Europe Granulocyte Colony Stimulating Factor Market by Route of Administration
- Chapter 3 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Company Profiles Overview
- 3.1 Market Competition Scenario Analysis
- 3.2 Overview of Major Market Players
- 3.3 Company Profiles
- 3.3.1 Novartis AG (Sandoz)
- 3.3.1.1 Company Overview
- 3.3.1.2 Business Description
- 3.3.1.3 Product Portfolio (Sandoz)
- 3.3.1.4 Key Financials
- 3.3.1.5 Key Developments
- 3.3.1.6 SWOT Analysis
- 3.3.2 Pfizer Inc.
- 3.3.2.1 Company Overview
- 3.3.2.2 Business Description
- 3.3.2.3 Product Portfolio
- 3.3.2.4 Key Financials
- 3.3.2.5 Key Developments
- 3.3.2.6 SWOT Analysis
- 3.3.3 Amgen Inc.
- 3.3.3.1 Company Overview
- 3.3.3.2 Business Description
- 3.3.3.3 Product Portfolio
- 3.3.3.4 Key Financials
- 3.3.3.5 SWOT Analysis
- 3.3.4 Teva Pharmaceutical Industries Ltd.
- 3.3.4.1 Company Overview
- 3.3.4.2 Business Description
- 3.3.4.3 Product Portfolio
- 3.3.4.4 Key Financials
- 3.3.4.5 Key Developments
- 3.3.4.6 SWOT Analysis
- 3.3.5 Stada Arzneimittel AG
- 3.3.5.1 Company Overview
- 3.3.5.2 Business Description
- 3.3.5.3 Product Portfolio
- 3.3.5.4 Key Financials
- 3.3.5.5 Key Developments
- 3.3.5.6 SWOT Analysis
- 3.3.6 Dr. Reddy's Laboratories Ltd.
- 3.3.6.1 Company Overview
- 3.3.6.2 Business Description
- 3.3.6.3 Product Portfolio
- 3.3.6.4 Key Financials
- 3.3.6.5 Key Developments
- 3.3.6.6 SWOT Analysis
- 3.3.7 Intas Pharmaceuticals Ltd
- 3.3.7.1 Company Overview
- 3.3.7.2 Business Description
- 3.3.7.3 Product Portfolio
- 3.3.7.4 Key Financials
- 3.3.8 Biocon Ltd.
- 3.3.8.1 Company Overview
- 3.3.8.2 Business Description
- 3.3.8.3 Product Portfolio
- 3.3.8.4 Key Financials
- 3.3.8.5 Key Developments
- 3.3.9 Dong-A Socio Holdings Co., Ltd
- 3.3.9.1 Company Overview
- 3.3.9.2 Business Description
- 3.3.9.3 Product Portfolio
- 3.3.10 BioCad
- 3.3.10.1 Company Overview
- 3.3.10.2 Business Description
- 3.3.10.3 Product Portfolio
- 3.3.1 Novartis AG (Sandoz)
- Chapter 4 Methodology and Data Source
- 4.1 Methodology/Research Approach
- 4.1.1 Market Size Estimation
- 4.2 Market Breakdown and Data Triangulation
- 4.3 Data Source
- 4.3.1 Secondary Sources
- 4.3.2 Primary Sources
- 4.1 Methodology/Research Approach
- Chapter 5 About Us
- 5.1 Who we are:
- Chapter 6 Disclaimer
- Chapter 1 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Overview
-
Inquiry Form
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
Request for Customization
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!